Diversity, Equity, and Inclusion in Multiple Myeloma: A Call to Action

Area of Science:

• Hematology
• Oncology
• Health Equity

Background:

• Multiple myeloma therapies have advanced, but racial and social inequities hinder uniform patient benefit.
• Disparities in accessing treatments and clinical trials affect diverse populations.
• The impact of health inequities on multiple myeloma care requires further understanding and strategic development.

Purpose of the Study:

• To identify disparities in multiple myeloma care based on race, age, socioeconomic status, and sexual orientation.
• To explore barriers to clinical trial participation for underrepresented groups.
• To recommend strategies for advanced practitioners to improve access and reduce underrepresentation in myeloma care.

Main Methods:

• A literature review was conducted using PubMed and CINAHL.
• Search terms included myeloma, bias, diversity, racial disparity, inequity, socioeconomic factors, trial, elderly, and sexual orientation.
• Relevant articles were identified to analyze disparities, barriers, and recommendations.

Main Results:

• Racial and socioeconomic inequities significantly impact survival and quality of care for underrepresented and elderly patients.
• Existing inequities reduce clinical trial enrollment, leading to adverse real-world outcomes.
• Structural, clinical, and attitudinal factors exacerbate challenges in equitable trial engagement.

Conclusions:

• Understanding health inequities is crucial for providing appropriate multiple myeloma care.
• Recommendations focus on education and enhancing treatment access to address disparities.
• Illuminating treatment disparities can dismantle barriers and foster a more equitable future for myeloma patients.